Barberry is two things from one shrub: a tart fruit and a bitter root. Most testing used the fruit, in short trials in one country. Cholesterol, blood fats and fasting blood sugar fall most steadily. Blood pressure and weight results contradict each other. Digestive upset is the reliable harm; pregnancy and prescription-medicine interference outweigh their evidence grade. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | Below 100 mg/dL; below 70 mg/dL with existing artery disease | Barberry's most consistent target |
| Apolipoprotein B | Below 80 mg/dL; below 60 mg/dL if high risk | Tracks risk better than LDL mass |
| Triglycerides | 50–90 mg/dL | Most responsive lipid to barberry |
| HDL cholesterol | 50–60 mg/dL (men), 60–70 mg/dL (women) | Detects the sex-specific response |
| Fasting glucose | 75–86 mg/dL | Detects both benefit and over-correction |
| HbA1c | 4.8–5.3% | Three-month sugar exposure |
| Fasting insulin and HOMA-IR | Insulin 2–5 µIU/mL; HOMA-IR below 1.5 | Barberry's most reproducible glucose-side signal |
| hs-CRP | Below 0.5 mg/L | Tracks the inflammation claim |
| ALT and AST | ALT below 20 U/L (men) and 17 U/L (women); AST similar | Detects liver strain from concentrated extract |
| Home blood pressure, seated | Below 120/80 mmHg | Contested benefit and additive-hypotension check |
| eGFR | Above 90 mL/min/1.73 m² | Baseline organ function before an interacting botanical |
| Blood lead | No established optimal target; track change from own baseline, staying below 3.5 µg/dL | Dried fruit from some regions exceeded lead limits |
Cadence: Baseline, then the full panel at 12 weeks and every 6 months on continued use; daily home glucose or blood pressure checks through the first 4 weeks for anyone on diabetes or blood pressure medication.